Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Exelixis Inc (NASDAQ: EXEL) closed at $45.23 in the last session, up 2.61% from day before closing price of $44.08. In other words, the price has increased by $2.61 from its previous closing price. On the day, 1.7 million shares were traded. EXEL stock price reached its highest trading level at $45.335 during the session, while it also had its lowest trading level at $44.02.
Ratios:
We take a closer look at EXEL’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.55. For the most recent quarter (mrq), Quick Ratio is recorded 3.68 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
On January 05, 2026, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $41.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when Haley Patrick J. bought 10,648 shares for $41.78 per share.
JOHNSON DAVID EDWARD bought 27,532 shares of EXEL for $1,187,235 on Nov 25 ’25. The Director now owns 1,553,262 shares after completing the transaction at $43.12 per share. On Nov 20 ’25, another insider, Haley Patrick J., who serves as the EVP, Commercial of the company, sold 34,187 shares for $41.88 each. As a result, the insider received 1,431,757 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXEL now has a Market Capitalization of 12176030720 and an Enterprise Value of 11314640896. As of this moment, Exelixis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.04, and their Forward P/E ratio for the next fiscal year is 13.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.30 while its Price-to-Book (P/B) ratio in mrq is 5.61. Its current Enterprise Value per Revenue stands at 4.945 whereas that against EBITDA is 13.311.
Stock Price History:
The Beta on a monthly basis for EXEL is 0.42, which has changed by 0.20601916 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, EXEL has reached a high of $49.62, while it has fallen to a 52-week low of $31.90. The 50-Day Moving Average of the stock is 5.18%, while the 200-Day Moving Average is calculated to be 11.23%.
Shares Statistics:
According to the various share statistics, EXEL traded on average about 2.80M shares per day over the past 3-months and 2568780 shares per day over the past 10 days. A total of 268.10M shares are outstanding, with a floating share count of 259.61M. Insiders hold about 3.17% of the company’s shares, while institutions hold 94.23% stake in the company. Shares short for EXEL as of 1767139200 were 24704144 with a Short Ratio of 8.82, compared to 1764288000 on 21360218. Therefore, it implies a Short% of Shares Outstanding of 24704144 and a Short% of Float of 12.72.
Earnings Estimates
Its stock is currently analyzed by 13.0 different market analysts. The consensus estimate for the next quarter is $0.73, with high estimates of $0.82 and low estimates of $0.59.
Analysts are recommending an EPS of between $3.18 and $2.16 for the fiscal current year, implying an average EPS of $2.95. EPS for the following year is $3.39, with 12.0 analysts recommending between $3.91 and $2.55.
Revenue Estimates
According to 9 analysts,. The current quarter’s revenue is expected to be $607.26M. It ranges from a high estimate of $618M to a low estimate of $597M. As of. The current estimate, Exelixis Inc’s year-ago sales were $566.75MFor the next quarter, 9 analysts are estimating revenue of $609.8M. There is a high estimate of $626.35M for the next quarter, whereas the lowest estimate is $593.67M.
A total of 10 analysts have provided revenue estimates for EXEL’s current fiscal year. The highest revenue estimate was $2.34B, while the lowest revenue estimate was $2.32B, resulting in an average revenue estimate of $2.33B. In the same quarter a year ago, actual revenue was $2.17BBased on 17 analysts’ estimates, the company’s revenue will be $2.6B in the next fiscal year. The high estimate is $2.75B and the low estimate is $2.5B.
